​

10x Genomics (TXG) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TXG Stock Forecast

10x Genomics (TXG) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $17.00, with a high of $22.00 and a low of $13.00. This represents a 10.03% increase from the last price of $15.45.

$10 $20 $30 $40 $50 $60 High: $22 Avg: $17 Low: $13 Last Closed Price: $15.45

TXG Stock Rating

10x Genomics stock's rating consensus is Hold, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (40.91%), 12 Hold (54.55%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Hold
Total 22 0 1 12 9 Strong Sell Sell Hold Buy Strong Buy

TXG Price Target Upside V Benchmarks

TypeNameUpside
Stock10x Genomics10.03%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Information Services Stocks 25.96%

Price Target Trends

1M3M12M
# Anlaysts225
Avg Price Target$21.00$21.00$17.00
Last Closing Price$15.45$15.45$15.45
Upside/Downside35.92%35.92%10.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 252510--17
Nov, 252510--17
Oct, 252510--17
Sep, 25259--16
Aug, 25259--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 15, 2025Barclays$22.00$15.4542.39%42.39%
Dec 01, 2025Kallum TitchmarshMorgan Stanley$20.00$18.0810.62%29.45%
Aug 11, 2025Kyle MiksonCanaccord Genuity$16.00$12.3929.14%3.56%
Aug 08, 2025Dan LeonardUBS$13.00$12.038.06%-15.86%
Aug 13, 2024Tejas SavantMorgan Stanley$46.00$19.65134.10%197.73%
Jul 23, 2024Kyle MiksonCanaccord Genuity$32.00$18.1176.70%107.12%
Jul 10, 2024Justin BowersDeutsche Bank$25.00$18.2536.99%61.81%
Jun 28, 2024Luke SergottBarclays$24.00$19.8520.91%55.34%
Jun 03, 2024Tycho PetersonJefferies$24.00$22.427.05%55.34%
May 01, 2024Luke SergottBarclays$36.00$29.2822.95%133.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 15, 2025BarclaysOverweightOverweighthold
Dec 11, 2025CitigroupBuyNeutraldowngrade
Aug 08, 2025UBSNeutralNeutralhold
Jun 24, 2025BarclaysOverweightOverweighthold
Oct 30, 2024UBSNeutralNeutralhold
Oct 16, 2024Cowen & Co.HoldHoldhold
Oct 10, 2024UBSBuyBuyhold
Sep 03, 2024UBSBuyBuyhold
Aug 13, 2024UBSBuyBuyhold
Jul 22, 2024JefferiesHoldBuyupgrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.37$-0.53$-1.46$-2.18$-1.52----
Avg Forecast$-1.47$-0.46$-1.62$-2.14$-1.41$-1.27$-0.91$-0.86$-1.07
High Forecast$-1.35$-0.43$-1.55$-1.73$-1.35$-1.12$-0.04$-0.71$-1.01
Low Forecast$-1.57$-0.49$-1.68$-2.31$-1.47$-1.52$-1.41$-1.09$-1.13
Surprise %265.31%15.22%-9.88%1.87%7.80%----

Revenue Forecast

$250M $370M $490M $610M $730M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$298.85M$490.49M$516.41M$618.73M$610.78M----
Avg Forecast$286.92M$493.74M$508.11M$616.72M$604.92M$630.74M$687.60M$739.28M$791.90M
High Forecast$301.81M$519.37M$521.63M$617.30M$611.79M$659.73M$688.66M$746.52M$829.91M
Low Forecast$268.82M$462.60M$491.46M$615.68M$598.81M$608.74M$686.53M$732.03M$761.89M
Surprise %4.16%-0.66%1.63%0.32%0.97%----

Net Income Forecast

$-7B $-6B $-4B $-3B $-1B $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-542.73M$-58.22M$-166.00M$-255.10M$-182.63M----
Avg Forecast$-5.67B$-64.96M$-86.08M$-255.10M$-165.42M$-158.30M$-119.69M$-105.37M$-124.98M
High Forecast$-4.54B$-51.97M$-68.86M$-204.08M$-158.48M$-131.42M$-4.13M$-83.35M$-118.82M
Low Forecast$-6.81B$-77.95M$-103.29M$-306.12M$-172.36M$-177.53M$-165.29M$-127.39M$-132.77M
Surprise %-90.43%-10.37%92.85%-10.40%----

TXG Forecast FAQ

Is 10x Genomics stock a buy?

10x Genomics stock has a consensus rating of Hold, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that 10x Genomics is a neutral investment for most analysts.

What is 10x Genomics's price target?

10x Genomics's price target, set by 22 Wall Street analysts, averages $17 over the next 12 months. The price target range spans from $13 at the low end to $22 at the high end, suggesting a potential 10.03% change from the previous closing price of $15.45.

How does 10x Genomics stock forecast compare to its benchmarks?

10x Genomics's stock forecast shows a 10.03% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the healthcare information services stocks industry (25.96%).

What is the breakdown of analyst ratings for 10x Genomics over the past three months?

  • December 2025: 11.76% Strong Buy, 29.41% Buy, 58.82% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 11.76% Strong Buy, 29.41% Buy, 58.82% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 11.76% Strong Buy, 29.41% Buy, 58.82% Hold, 0% Sell, 0% Strong Sell.

What is 10x Genomics’s EPS forecast?

10x Genomics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.27, marking a -16.45% decrease from the reported $-1.52 in 2024. Estimates for the following years are $-0.91 in 2026, $-0.86 in 2027, and $-1.07 in 2028.

What is 10x Genomics’s revenue forecast?

10x Genomics's average annual revenue forecast for its fiscal year ending in December 2025 is $630.74M, reflecting a 3.27% increase from the reported $610.78M in 2024. The forecast for 2026 is $687.6M, followed by $739.28M for 2027, and $791.9M for 2028.

What is 10x Genomics’s net income forecast?

10x Genomics's net income forecast for the fiscal year ending in December 2025 stands at $-158M, representing a -13.32% decrease from the reported $-183M in 2024. Projections indicate $-120M in 2026, $-105M in 2027, and $-125M in 2028.